{"classes":[{"categories":[{"measurements":[{"comment":"NA=DOR upper limit not reached at time of data cutoff due to insufficient number of responding participants with relapse","groupId":"OG000","lowerLimit":"2.2","upperLimit":"NA","value":"12.2"},{"comment":"NA=Median DOR not reached at time of data cutoff due to insufficient number of responding participants with relapse\n\nNA=DOR lower limit not reached at time of data cutoff due to insufficient number of responding participants with relapse\n\nNA=DOR upper limit not reached at time of data cutoff due to insufficient number of responding participants with relapse","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"For participants who demonstrated a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, Duration of Response (DOR) was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR.","dispersionType":"Full Range","groups":[{"description":"Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to \\~2 years).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"All randomized participants, regardless of whether or not they received study treatment, who demonstrated a confirmed response (CR or PR). Participants were included in the treatment arm to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 36 months (from time of first documented evidence of CR or PR through Final Analysis database cutoff date of 11-April-2019)","title":"Duration of Response Per RECIST 1.1 in All Participants Who Had a Confirmed Response","type":"SECONDARY","unitOfMeasure":"Months"}